Diplomat Pharmacy, Inc. (NYSE:DPLO) reported Q2 2017 earnings this Afternoon, coming in at $0.25 per share, beating Wall Street’s estimates of $0.15 per Share. Revenue for the quarter came in at $1.13 billion missing the streets estimates of $1.14 billion
Analyst Coverage For Diplomat Pharmacy, Inc. (NYSE:DPLO)
These are 1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings .
The current consensus rating for Diplomat Pharmacy, Inc. (NYSE:DPLO) is Hold (Score: 2.09) with a consensus target price of $17.89 , a potential (17.25% upside)Recent Insider Trading for Diplomat Pharmacy, Inc. (NYSE:DPLO)
- On 9/15/2016 Atheer A Kaddis, EVP, sold 20,000 with an average share price of $30.12 per share and the total transaction amounting to $602,400.00.
- On 8/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $35.76 per share and the total transaction amounting to $440,742.00.
- On 7/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $35.04 per share and the total transaction amounting to $431,868.00.
- On 6/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $32.31 per share and the total transaction amounting to $398,220.75.
- On 5/2/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $30.17 per share and the total transaction amounting to $371,845.25.
- On 4/15/2016 Atheer A Kaddis, EVP, sold 24,650 with an average share price of $30.00 per share and the total transaction amounting to $739,500.00.
Recent Trading for Diplomat Pharmacy, Inc. (NYSE:DPLO) Shares of Diplomat Pharmacy, Inc. closed the previous trading session at 15.26 up +0.44 2.97% with 862,978 shares trading hands.